- Kraig Biocraft Laboratories (OTCQB: KBLB) is executing its largest-ever batch of recombinant spider silk production.
- The completion of the first half of the production is achieved, with the second half expected within 14 days.
- BAM-1 hybrid production shows promising results, ensuring consistent supply for future production cycles.
Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB), a pioneer in spider silk technology, has announced significant advancements in its recombinant spider silk production. The company is in the process of completing its largest-ever production batch, having successfully finished the first half. The resulting spider silk cocoons are being prepared for reeling, and the completion of the second half of the production cycle is anticipated in two weeks.
This production cycle signifies a milestone for Kraig Labs as the first simultaneous BAM-1 batches are produced in the company's newest facilities. Initial results are highly encouraging, demonstrating the robustness of BAM-1 hybrids and the efficiency of its expanded production infrastructure. Additionally, the successful operation of multiple concurrent batches illustrates the scalability and reliability of the company's model, shifting from batch processing to continuous flow manufacturing.
Furthermore, Kraig Labs has prepared all BAM-1 hybrid eggs for release next month, ensuring a steady supply for upcoming production cycles. CEO Kim Thompson stated, "The successful execution of simultaneous production batches in our new facilities demonstrates the scalability of our technology from batch processing to continuous flow manufacturing." With these advancements, the company is well-positioned to accelerate the growth and commercialization of its high-performance, eco-friendly spider silk fibers.
